Pregnancy Outcome After Secondary Recurrent Pregnancy Loss (sRPL) is Influenced by Sex of the First Born Child and Maternal Carriage of HY-restricting HLA Class II Alleles
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Aalborg University Hospital
- Enrollment
- 583
- Locations
- 1
- Primary Endpoint
- Live birth or prolonged pregnancy in patients with ≥1 HY restricted HLA class II allele
Study Overview
Brief Summary
This cross-sectional and prospective cohort study will investigate if sRPL patients with a first born boy who carry ≥1 HY-restricting (HY-r) HLA class II alleles are associated with a lower chance for a succesful reproductive outcome in first pregnancy after admission compared to sRPL patients with a first born girl carrying ≥1 HY-r HLA class II alleles and women with no HY-r HLA class II alleles and a firstborn boy. Also, the study will compare sRPL patients with a firstborn boy who do not carry a HY-r HLA class II allele with sRPL patients having a firstborn girl and carrying no such alleles.
We hypothesize that sRPL patients with a first born boy compared to sRPL patients with a firstborn girl who carry ≥1 HY-r HLA class II alleles is associated with a negative prognosis, while no association between sex of firstborn child and pregnancy outcome is expected in sRPL carrying no HY-r HLA class II alleles. Neither do we expect an association between pregnancy outcome and carriage of HY-r HLA class II alleles in pRPL patients.
Detailed Description
In a Danish cohort (Kolte et al., 2016, Nielsen et al., 2009) the first pregnancy outcome after admission and the long term live birth rate were associated with carriage of known HY-r HLA class II alleles in the sRPL patient with a first born boy, but not in the sRPL with a first born girl. The live birth rate in the first pregnancy after admission and the hazard ratio for live birth on longterm were comparable between sRPL with a first born girl and boy if the sRPL did not carry a HY-r HLA class II allele. In contrast, sRPL after a first born boy had a significant poorer prognosis than sRPL after a first born girl when the patients carried ≥1 HY-r HLA class II allele.
These findings were the first of its kind and it has not been confirmed in other cohorts ever since. In a new Danish cohort from another region of Denmark, this study will examine if these findings can be replicated.
Before data collection, a sample size calculation was performed based on the findings in the former studies (Nielsen et al., 2009; Kolte et al., 2016). These studies differ from the present study, since Nielsen et al. (2009) included HLA DRB3*0301 but not HLA DRB1*07 as a HY-r allele, and Kolte et al.(2016) included HLA DRB3*0301 too and measured the cumulative live birth rate in contrast to first pregnancy outcome measured in the present study. However, the sample size calculation based on weighted calculations on results from these studies is the closest we get a suitable sample size for the present study. The sample size in the present study should consist of at least 88 sRPL patients with a first born boy with maternal HY-r HLA class II allele and 73 sRPL patients with a firstborn boy and no maternal HY-r HLA class II alleles on weighted calculations with an alpha level = 0.05, a power of 80 %, and a inclusion ratio of 1.2 more with than without such HLA carriage. The sample size needed to find difference between women with a firstborn boy vs girl with such HLA carriage was smaller; ie. 48 patients for comparing patients with ≥1 HY-r HLA alleles. As this was the primary aim, this sample size was considered sufficient for the study.
Study inclusion started January 1, 2016, and will end when this sample size is reached.
The anticipated sample size of the pRPL group is 1.2 times the total number of sRPL patients since pRPL normally account for about 55 % of RPL patients. Thus, 180 patients are expected in the pRPL, although this is not taking into account when deciding the timing for final follow-up and data collection.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 45 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •≥ 3 consecutive pregnancy losses before admission
Exclusion Criteria
- •Significant uterine malformation
- •Chromosomal abnormalities
Outcomes
Primary Outcomes
Live birth or prolonged pregnancy in patients with ≥1 HY restricted HLA class II allele
Time Frame: Through study completion, i.e. up to 5 years
The number of patients with a live birth or prolonged pregnancy (\>12 weeks) in first pregnancy after referral with 1-2 HY.-restricted HLA class II allele
Live birth or prolonged pregnancy in patients with 0 HY-restricted HLA class II allele
Time Frame: Through study completion, i.e. up to 5 years
The number of patients with a live birth or prolonged pregnancy (\>12 weeks) in first pregnancy after referral in patients with no HY-restricted HLA class II allele
Secondary Outcomes
- Maternal prevalence of 0 HY-restricted HLA Class II alleles(Measured on the date of study entry and assessed within 2 weeks for each individual during study completion period, i.e. up to 5 years)
- Maternal prevalence of ≥1 HY-restricted HLA Class II alleles(Measured on the date of study entry and assessed within 2 weeks for each individual during study completion period, i.e. up to 5 years)
- Maternal prevalence of HLA DRB1*15(Measured on the date of study entry and assessed within 2 weeks for each individual during study completion period, i.e. up to 5 years)
- Maternal prevalence of HLA DRB1*01 or HLA DRB1*10(Measured on the date of study entry and assessed within 2 weeks for each individual during study completion period, i.e. up to 5 years)
- Maternal prevalence of HLA DRB1*07(Measured on the date of study entry and assessed within 2 weeks for each individual during study completion period, i.e. up to 5 years)
- Maternal prevalence of HLA DRB1*03(Measured on the date of study entry and assessed within 2 weeks for each individual during study completion period, i.e. up to 5 years)
- Sex ratio of the children born after RPL(Assessed at the date of study completion, i.e. after 5 years)
- Sex ratio of the children born before sRPL(Baseline)
Investigators
Caroline Nørgaard-Pedersen
Principal investigator
Aalborg University Hospital
